Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/10/2025

Management of Uncontrolled Hypertension Despite Current Therapy

Current Medication Analysis

  • The European Heart Journal recommends adding a thiazide diuretic such as chlorthalidone to the current regimen for a patient with uncontrolled hypertension despite being on losartan and amlodipine 1
  • Diclofenac sodium (NSAID) can attenuate the antihypertensive effects of ARBs like losartan, according to Hypertension 2
  • Cyclosporine 0.05% ophthalmic solution could potentially have systemic effects, as noted in Hypertension 2
  • Clonidine 0.1 mg may be contributing to blood pressure control but requires careful dosing and monitoring, as stated in Circulation 3

Step-by-Step Management Approach

  • The European Heart Journal suggests ensuring chlorthalidone 25 mg is being taken daily as part of the core antihypertensive regimen 1
  • Assessing medication adherence is crucial, as non-adherence is a common cause of treatment failure in hypertension, according to Hypertension 4
  • Chemical adherence testing can be used to confirm which medications are being taken regularly, as recommended in Hypertension 4
  • Simplifying the regimen can improve adherence, potentially using combination pills, as noted in a medical guideline 5

Monitoring and Treatment

  • Adding spironolactone 25 mg daily can be effective in resistant hypertension, as stated in Circulation and the European Heart Journal 1, 3
  • If spironolactone is not tolerated, consider eplerenone or amiloride as alternatives, according to the European Heart Journal 1
  • Discontinuing diclofenac or switching to a non-NSAID analgesic can eliminate its BP-raising effect, as recommended in Hypertension 2
  • The target blood pressure should be 120-129/70-79 mmHg, according to recent guidelines from the European Heart Journal 1

Special Considerations

  • Gabapentin and duloxetine can impact overall medication burden and potential for interactions, as noted in Hypertension 2
  • The European Heart Journal recommends avoiding adding another RAS blocker to losartan, as dual RAS blockade increases adverse effects without additional benefit 1